Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders.

ABSTRACT: The visual system offers unparalleled precision in the assessment of neuroaxonal damage. With the majority of patients with multiple sclerosis (MS) experiencing afferent and efferent visual dysfunction, outcome measures capturing these deficits provide insight into neuroaxonal injury, even in those with minimal disability. Ideal for use in clinical trials, visual measures are generally inexpensive, accessible, and reproducible. Quantification of visual acuity, visual fields, visual quality of life, and electrophysiologic parameters allows assessment of function, whereas optical coherence tomography (OCT) provides reliable measures of the structural integrity of the anterior afferent visual pathway. The technology of oculomotor biometrics continues to advance, and discrete measures of fixat

SUBMITTER: Graves JS 

PROVIDER: S-EPMC8711076 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature